News

Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense ...
Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous ...
TheCable5d
Lessons from Kenya’s e-procurement revolution
Kenya’s e-GP system is now saving the country an estimated KES 85.9 billion annually, or roughly 0.9 percent of GDP, by ...